1IA
REGN icon

1620 Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

1620 Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$801 – 711
2024
Q4 		$801 Hold
1
– – ﹤0.01% 651
2024
Q3 		$1.18K Buy
+1
New +$1.11K ﹤0.01% 604

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1620 Investment Advisors's REGN Position: Q1 2025 in Review

1620 Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1 share — an estimated $801 sold.

1620 Investment Advisors first reported a position in REGN in Q3 2024 and held it in 2 quarters. The position peaked at $1.18K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • 1620 Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • 1620 Investment Advisors sold 1 Regeneron Pharmaceuticals share in Q1 2025, an estimated $801.
  • 1620 Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • 1620 Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.18K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on 1620 Investment Advisors's 13F filing for Q1 2025, filed 14 May 2025.